(Alliance News) - Astrazeneca on Friday hailed positive results from a phase-three trial of its asthma treatment breztri aerosphere. Shares in the Cambridge, England-based pharmaceutical company rose ...

Budesonide–formoterol reliever therapy significantly reduces airway inflammation vs SABA in adults with mild to moderate asthma using ICS.

Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol fumarate or ...

Besides Wall Street's top-and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to ...

Full results from the positive Phase III KALOS and LOGOS trials have been published in The Lancet Respiratory Medicine.

AZN gears up for Q4 results as cancer, diabetes and rare disease drugs drive sales expectations ahead of the Feb. 10 earnings report.

AstraZeneca AZN reported fourth-quarter 2025 core earnings of $2.12 per share, which missed the Zacks Consensus Estimate of $2.18 per share. Earnings rose 1% year over year on a reported basis but ...

AstraZeneca Plc AZN on Tuesday reported fourth-quarter 2025 sales of $15.50 billion, up 4% year over year (+2% at constant currency or cc), almost in line with the consensus of $15.49 billion. The ...

President Donald J. Trump announced the launch of TrumpRx, the direct-to-consumer drug website that features reduced prices ...

Adults with mild-to-moderate asthma who take regular inhaled corticosteroids can achieve greater control of airway inflammation by also using the 2-in-1 combination budesonide-formoterol as a reliever ...

MyPrize, the world's fastest-growing multiplayer social gaming and entertainment platform, announced a new partnership with ...

Insmed Incorporated , a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced ...